Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant B lymphocytes
- PMID: 7678518
Expression and function of a receptor for hyaluronan-mediated motility on normal and malignant B lymphocytes
Abstract
Migration through extracellular matrix is fundamental to malignant invasion. A receptor for hyaluronan-mediated motility (RHAMM) has previously been shown to play a fundamental role in locomotion of ras-transformed cells as well as functioning in signal transduction. Expression of RHAMM was characterized on B lymphocytes from normal and malignant lymphoid tissues using multiparameter phenotypic immunofluorescence analysis as well as functional analysis of its role in locomotion of malignant hairy cell leukemia B cells. RHAMM is not detectable on most normal B cells located in blood, spleen, or lymph node, but it is detectable on bone marrow and thymic B cells. Among B-cell malignancies, it is expressed on most terminally differentiated B cells from multiple myeloma bone marrows, is present on a subset of non-Hodgkin's lymphomas, and is absent on B chronic lymphocytic leukemia. Activation of peripheral blood B cells by Staphylococcus A cowan (SAC), but not by pokeweed mitogen, induced transient expression of RHAMM at day 3 of culture, suggesting RHAMM may be used by antigen-activated normal B cells. For malignant cells, expression of RHAMM increased on long-term culture of bone marrow plasma cells from multiple myeloma patients, indicating prolonged expression in contrast to the transient expression on SAC-activated normal B cells. Intriguingly, RHAMM was expressed on hairy leukemia cells located in spleen but absent from those in peripheral blood of the same patient. RHAMM, as expressed on splenic hairy cells, was a 58-Kd molecule that binds hyaluronan, is encoded by a 5.2-kb messenger RNA, and participates in locomotion by these cells. Hairy cells locomoted in response to hyaluronan at 4 mu per minute. Monoclonal antibody to RHAMM inhibited this locomotion almost completely as detected using video time-lapse cinemicrography. These observations are consistent with a role for RHAMM in malignant invasion and metastatic growth.
Similar articles
-
RHAMM, a receptor for hyaluronan-mediated motility, on normal human lymphocytes, thymocytes and malignant B cells: a mediator in B cell malignancy?Leuk Lymphoma. 1994 Aug;14(5-6):363-74. doi: 10.3109/10428199409049691. Leuk Lymphoma. 1994. PMID: 7529076 Review.
-
Regulated expression of a receptor for hyaluronan-mediated motility on human thymocytes and T cells.J Immunol. 1993 May 15;150(10):4292-302. J Immunol. 1993. PMID: 7683315
-
Hyaluronan-dependent motility of B cells and leukemic plasma cells in blood, but not of bone marrow plasma cells, in multiple myeloma: alternate use of receptor for hyaluronan-mediated motility (RHAMM) and CD44.Blood. 1996 Mar 1;87(5):1891-9. Blood. 1996. PMID: 8634437
-
Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants.Blood. 1999 Mar 1;93(5):1684-96. Blood. 1999. PMID: 10029598
-
Hyaluronan: RHAMM mediated cell locomotion and signaling in tumorigenesis.J Neurooncol. 1995 Dec;26(3):221-9. doi: 10.1007/BF01052625. J Neurooncol. 1995. PMID: 8750188 Review.
Cited by
-
Smart Nanoparticles Based on Hyaluronic Acid for Redox-Responsive and CD44 Receptor-Mediated Targeting of Tumor.Nanoscale Res Lett. 2015 Dec;10(1):981. doi: 10.1186/s11671-015-0981-5. Epub 2015 Jul 11. Nanoscale Res Lett. 2015. PMID: 26163139 Free PMC article.
-
Intratumoral delivery of Paclitaxel in solid tumor from biodegradable hyaluronan nanoparticle formulations.AAPS PharmSciTech. 2009;10(2):410-7. doi: 10.1208/s12249-009-9222-5. Epub 2009 Apr 21. AAPS PharmSciTech. 2009. PMID: 19381833 Free PMC article.
-
Cell adhesion molecules.Clin Mol Pathol. 1996 Dec;49(6):M321-30. doi: 10.1136/mp.49.6.m321. Clin Mol Pathol. 1996. PMID: 16696098 Free PMC article. No abstract available.
-
Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma.Blood. 2005 Jun 15;105(12):4836-44. doi: 10.1182/blood-2004-10-3825. Epub 2005 Feb 24. Blood. 2005. PMID: 15731173 Free PMC article.
-
Interplay of mevalonate and Hippo pathways regulates RHAMM transcription via YAP to modulate breast cancer cell motility.Proc Natl Acad Sci U S A. 2014 Jan 7;111(1):E89-98. doi: 10.1073/pnas.1319190110. Epub 2013 Dec 23. Proc Natl Acad Sci U S A. 2014. PMID: 24367099 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials